Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Our Strengths
Our key strengths include the following:
-
Sales growth of our commercialized asset.
-
Proven rare-disease commercialization capabilities.
-
Internal pipeline of product candidates.
-
Transgenic Production Platform Technology.
-
Data exclusivity, know-how and intellectual property.
Our Strategy
Our goal is to be a leading biopharmaceutical company focused on offering treatment options for patients with unmet medical needs, focused on rare diseases.
Our three-pillar strategy for achieving our goal is:
-
Continuing to grow sales of our commercialized asset through further country launches.
-
Expanding indications for rhC1INH and clinical development and commercialization of new recombinant human proteins using our platform technology.
-
In-licensing or acquiring drug candidates that are in the late-stages of clinical development and that can potentially leverage our commercial infrastructure.
Taal aanpassen
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.